These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37941560)

  • 1. Corrigendum: C-reactive protein is an indicator of the immunosuppressive microenvironment fostered by myeloid cells in hepatocellular carcinoma.
    Wang Y; Li Z; Huang Z; Yu X; Zheng L; Xu J
    Front Oncol; 2023; 13():1280727. PubMed ID: 37941560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-Reactive Protein Is an Indicator of the Immunosuppressive Microenvironment Fostered by Myeloid Cells in Hepatocellular Carcinoma.
    Wang Y; Li Z; Huang Z; Yu X; Zheng L; Xu J
    Front Oncol; 2021; 11():774823. PubMed ID: 35070979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum: Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma.
    Zhang T; Nie Y; Gu J; Cai K; Chen X; Li H; Wang J
    Front Oncol; 2021; 11():843623. PubMed ID: 35111689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Effects of alkalization therapy on hepatocellular carcinoma: a retrospective study.
    Isowa M; Hamaguchi R; Narui R; Morikawa H; Wada H
    Front Oncol; 2023; 13():1291026. PubMed ID: 37799473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.
    Hu X; Bao M; Huang J; Zhou L; Zheng S
    Front Oncol; 2020; 10():617539. PubMed ID: 33330112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Single-cell technologies to decipher the immune microenvironment in myeloid neoplasms: Perspectives and opportunities.
    Caprioli C; Nazari I; Milovanovic S; Pelicci PG
    Front Oncol; 2022; 12():974476. PubMed ID: 36046050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.
    Yu S; Zhu Q; Zheng Y; Wu C; Ren H; Liu X; Liu Z; Li Y; Pan Q; Zheng YJ
    Front Oncol; 2022; 12():950499. PubMed ID: 36203441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: SPOCK1 promotes the development of hepatocellular carcinoma.
    Váncza L; Karászi K; Péterfia B; Turiák L; Dezső K; Sebestyén A; Reszegi A; Petővári G; Kiss A; Schaff Z; Baghy K; Kovalszky I
    Front Oncol; 2023; 13():1203745. PubMed ID: 37152016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum: Ribosomal protein L23 drives the metastasis of hepatocellular carcinoma
    Yang M; Zhou Y; Deng H; Zhou H; Cheng S; Zhang D; He X; Mai L; Chen Y; Chen J
    Front Oncol; 2024; 14():1373034. PubMed ID: 38525425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.
    Lai Y; Feng B; Abudoureyimu M; Zhi Y; Zhou H; Wang T; Chu X; Chen P; Wang R
    Front Oncol; 2020; 10():277. PubMed ID: 32195187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: Loss of TARBP2 Drives the Progression of Hepatocellular Carcinoma
    Li LM; Chen C; Ran RX; Huang JT; Sun HL; Zeng C; Zhang Z; Zhang W; Liu SM
    Front Oncol; 2021; 11():746958. PubMed ID: 34557419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1233247. PubMed ID: 37427117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis
    Wen J; Aili A; Yan YX; Lai Y; Niu S; He S; Zhang X; Zhang G; Li J
    Front Oncol; 2022; 12():1038279. PubMed ID: 36387066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: ASPM is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma and liver hepatocellular carcinoma.
    Deng T; Liu Y; Zhuang J; Tang Y; Huo Q
    Front Oncol; 2022; 12():979968. PubMed ID: 36072794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients.
    Chen P; Song H; Xu W; Guo J; Wang J; Zhou J; Kang X; Jin C; Cai Y; Feng Z; Gao H; Lu F; Li L
    Front Oncol; 2023; 13():1170066. PubMed ID: 37152060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: CDT1 is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
    Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
    Front Oncol; 2021; 11():801970. PubMed ID: 34900749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma.
    Lei Y; Wang X; Sun H; Fu Y; Tian Y; Yang L; Wang J; Xia F
    Front Oncol; 2024; 14():1438731. PubMed ID: 39050582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: Fat fraction quantification with MRI estimates tumor proliferation of hepatocellular carcinoma.
    Huang M; Zhang F; Li Z; Luo Y; Li J; Wang Z; Ma L; Chen G; Hu X
    Front Oncol; 2024; 14():1418905. PubMed ID: 38841171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma.
    Che L; Paliogiannis P; Cigliano A; Pilo MG; Chen X; Calvisi DF
    Front Oncol; 2022; 12():874053. PubMed ID: 35494002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: YY1 Promotes Endothelial Cell-Dependent Tumor Angiogenesis in Hepatocellular Carcinoma by Transcriptionally Activating VEGFA.
    Yang W; Li Z; Qin R; Wang X; An H; Wang Y; Zhu Y; Liu Y; Cai S; Chen S; Sun T; Meng J; Yang C
    Front Oncol; 2021; 11():828861. PubMed ID: 35096629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.